Cellular Reprogramming of Human Peripheral Blood Cells

Genomics, Proteomics and Bioinformatics

Volumn 11, Issue 5, 2013, Pages 264-274

  Zhang, Xiao Bing ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell fate conversion; Hematopoietic cells; Induced pluripotent stem cells; Peripheral blood; Reprogramming

Indexed keywords

KRUPPEL LIKE FACTOR 4; LENTIVIRUS VECTOR; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN BCL XL; PROTEIN P53; TRANSCRIPTION FACTOR SOX2;

CELL FATE; CELL REPROGRAMMING; CELL THERAPY; EPISOME; GENE EXPRESSION; GENOME; HUMAN; INTERNAL RIBOSOME ENTRY SITE; LIVER CELL; MESENCHYMAL STEM CELL; NERVE CELL; NONHUMAN; NUCLEAR REPROGRAMMING; PERIPHERAL BLOOD MONONUCLEAR CELL; PLURIPOTENT STEM CELL; PRODUCT SAFETY; PROTEIN DOMAIN; REGENERATIVE MEDICINE; REVIEW; SENDAI VIRUS; SKIN FIBROBLAST; SOMATIC CELL; STEM CELL TRANSPLANTATION;

SENDAI VIRUS;

CELL FATE CONVERSION; HEMATOPOIETIC CELLS; INDUCED PLURIPOTENT STEM CELLS; PERIPHERAL BLOOD; REPROGRAMMING;

ANIMALS; CELL DIFFERENTIATION; CELL- AND TISSUE-BASED THERAPY; GENETIC VECTORS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LEUKOCYTES; PROMOTER REGIONS, GENETIC;

EID: 84886406593     PISSN: 16720229     EISSN: 22103244     Source Type: Journal    
DOI: 10.1016/j.gpb.2013.09.001     Document Type: Review

References (136)

1. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., Maeshall V.S., et al. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282:1145-1147.
2. Campbell K.H., McWhir J., Ritchie W.A., Wilmut I. Sheep cloned by nuclear transfer from a cultured cell line. Nature 1996, 380:64-66.
3. Tachibana M., Amato P., Sparman M., Gutierrez N.M., Tippner-Hedges R., Ma H., et al. Human embryonic stem cells derived by somatic cell nuclear transfer. Cell 2013, 153:1228-1238.
4. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
5. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
6. Graf T. Historical origins of transdifferentiation and reprogramming. Cell Stem Cell 2011, 9:504-516.
7. Jaenisch R. Nuclear cloning and direct reprogramming: the long and the short path to Stockholm. Cell Stem Cell 2012, 11:744-747.
8. Daley G.Q. Cellular alchemy and the golden age of reprogramming. Cell 2012, 151:1151-1154.
9. Surani M.A. Cellular reprogramming in pursuit of immortality. Cell Stem Cell 2012, 11:748-750.
10. Liao J., Wu Z., Wang Y., Cheng L., Cui C., Gao Y., et al. Enhanced efficiency of generating induced pluripotent stem (iPS) cells from human somatic cells by a combination of six transcription factors. Cell Res 2008, 18:600-603.
11. Huangfu D., Osafune K., Maehr R., Guo W., Eijkelenboom A., Chen S., et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008, 26:1269-1275.
12. + cells into induced pluripotent stem cells with OCT4 and SOX2 alone. Mol Ther 2012, 20:408-416.
13. Ladewig J., Koch P., Brustle O. Leveling Waddington: the emergence of direct programming and the loss of cell fate hierarchies. Nat Rev Mol Cell Biol 2013, 14:225-236.
14. Abyzov A., Mariani J., Palejev D., Zhang Y., Haney M.S., Tomasini L., et al. Somatic copy number mosaicism in human skin revealed by induced pluripotent stem cells. Nature 2012, 492:438-442.
15. Sung L.Y., Gao S., Shen H., Yu H., Song Y., Simith S.L., et al. Differentiated cells are more efficient than adult stem cells for cloning by somatic cell nuclear transfer. Nat Genet 2006, 38:1323-1328.
16. Choi S.M., Liu H., Chaudhari P., Kim Y., Cheng L., Feng J., et al. Reprogramming of EBV-immortalized B-lymphocyte cell lines into induced pluripotent stem cells. Blood 2011, 118:1801-1805.
17. Rajesh D., Dickerson S.J., Yu J., Brown M.E., Thomson J.A., Seay N.J. Human lymphoblastoid B-cell lines reprogrammed to EBV-free induced pluripotent stem cells. Blood 2011, 118:1797-1800.
18. Okita K., Yamakawa T., Matsumura Y., Sato Y., Amano N., Watanabe A., et al. An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells 2013, 31:458-466.
19. Staerk J., Dawlaty M.M., Gao Q., Maetzel D., Hanna J., Sommer C.A., et al. Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell 2010, 7:20-24.
20. Loh Y.H., Hartung O., Li H., Guo C., Sahalie J.M., Manos P.D., et al. Reprogramming of T cells from human peripheral blood. Cell Stem Cell 2010, 7:15-19.
21. Nishimura T., Kaneko S., Kawana-Tachikawa A., Tajima Y., Goto H., Zhu D., et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 2013, 12:114-126.
22. Wakao H., Yoshikiyo K., Koshimizu U., Furukawa T., Enomoto K., Matsunaga T., et al. Expansion of functional human mucosal-associated invariant T cells via reprogramming to pluripotency and redifferentiation. Cell Stem Cell 2013, 12:546-558.
23. Chou B.K., Mali P., Huang X., Ye Z., Dowey S.N., Resar L.M., et al. Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res 2011, 21:518-529.
24. Dowey S.N., Huang X., Chou B.K., Ye Z., Cheng L. Generation of integration-free human induced pluripotent stem cells from postnatal blood mononuclear cells by plasmid vector expression. Nat Protoc 2012, 7:2013-2021.
25. Zaret K.S., Carroll J.S. Pioneer transcription factors: establishing competence for gene expression. Genes Dev 2011, 25:2227-2241.
26. Soufi A., Donahue G., Zaret K.S. Facilitators and impediments of the pluripotency reprogramming factors' initial engagement with the genome. Cell 2012, 151:994-1004.
27. Loh K.M., Lim B. A precarious balance: pluripotency factors as lineage specifiers. Cell Stem Cell 2011, 8:363-369.
28. Shu J., Wu C., Wu Y., Li Z., Shao S., Zhao W., et al. Induction of pluripotency in mouse somatic cells with lineage specifiers. Cell 2013, 153:963-975.
29. Montserrat N., Nivet E., Sancho-Martinez I., Hishida T., Kumar S., Miquel L., et al. Reprogramming of human fibroblasts to pluripotency with lineage specifiers. Cell Stem Cell 2013, 13:341-350.
30. Niwa H., Miyazaki J., Smith A.G. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 2000, 24:372-376.
31. Meng X., Su R.J., Baylink D.J., Neises A., Kiroyan J.B., Lee W.Y., et al. Rapid and efficient reprogramming of human fetal and adult blood CD34+ cells into mesenchymal stem cells with a single factor. Cell Res 2013, 23:658-672.
32. Kopp J.L., Ormsbee B.D., Desler M., Rizzino A. Small increases in the level of Sox2 trigger the differentiation of mouse embryonic stem cells. Stem Cells 2008, 26:903-911.
33. Zhao S., Nichols J., Smith A.G., Li M. SoxB transcription factors specify neuroectodermal lineage choice in ES cells. Mol Cell Neurosci 2004, 27:332-342.
34. Ring K.L., Tong L.M., Balestra M.E., Javier R., Andrews-Zwilling Y., Li G., et al. Direct reprogramming of mouse and human fibroblasts into multipotent neural stem cells with a single factor. Cell Stem Cell 2012, 11:100-109.
35. Guo G., Yang J., Nichols J., Hall J.S., Eyres I., Mansfield W., et al. Klf4 reverts developmentally programmed restriction of ground state pluripotency. Development 2009, 136:1063-1069.
36. Carey B.W., Markoulaki S., Hanna J.H., Faddah D.A., Buganim Y., Kim J., et al. Reprogramming factor stoichiometry influences the epigenetic state and biological properties of induced pluripotent stem cells. Cell Stem Cell 2011, 9:588-598.
37. Whyte W.A., Orlando D.A., Hnisz D., Abraham B.J., Lin C.Y., Kagey M.H., et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 2013, 153:307-319.
38. Wei Z., Gao F., Kim S., Yang H., Lyu J., An W., et al. Klf4 organizes long-range chromosomal interactions with the Oct4 locus in reprogramming and pluripotency. Cell Stem Cell 2013, 13:36-47.
39. Ban H., Nishishita N., Fusaki N., Tabata T., Saeki K., Shikamura M., et al. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc Natl Acad Sci U S A 2011, 108:14234-14239.
40. Nie Z., Hu G., Wei G., Cui K., Yamane A., Resch W., et al. C-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 2012, 151:68-79.
41. Lin C.Y., Loven J., Rahl P.B., Paranal R.M., Burge C.B., Bradner J.E., et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012, 151:56-67.
42. Okita K., Ichisaka T., Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007, 448:313-317.
43. Su R.-J., Baylink D.J., Neises A., Kiroyan J.B., Meng X., Payne K.J., et al. Efficient generation of integration-free iPS cells from human adult peripheral blood using BCL-XL together with yamanaka factors. PLoS One 2013, 8:e64496.
44. Martins-Taylor K., Xu R.H. Concise review: genomic stability of human induced pluripotent stem cells. Stem Cells 2012, 30:22-27.
45. Takenaka C., Nishishita N., Takada N., Jakt L.M., Kawamata S. Effective generation of iPS cells from CD34+ cord blood cells by inhibition of p53. Exp Hematol 2010, 38:154-162.
46. Marion R.M., Strati K., Li H., Murga M., Blanco R., Ortega S., et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009, 460:1149-1153.
47. Li Y., Feng H., Gu H., Lewis D.W., Yuan Y., Zhang L., et al. The p53-PUMA axis suppresses iPSC generation. Nat Commun 2013, 4:2174.
48. Zhang Y., Li W., Laurent T., Ding S. Small molecules, big roles - the chemical manipulation of stem cell fate and somatic cell reprogramming. J Cell Sci 2012, 125:5609-5620.
49. Mali P., Chou B.K., Yen J., Ye Z., Zou J., Dowey S., et al. Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells 2010, 28:713-720.
50. Liang G., Taranova O., Xia K., Zhang Y. Butyrate promotes induced pluripotent stem cell generation. J Biol Chem 2010, 285:25516-25521.
51. Zhang Z., Wu W.S. Sodium butyrate promotes generation of human induced pluripotent stem cells through induction of the miR302/367 cluster. Stem Cells Dev 2013, 22:2268-2277.
52. Saunders A., Faiola F., Wang J. Pursuing self-renewal and pluripotency with the stem cell factor Nanog. Stem Cells 2013, 31:1227-1236.
53. Shyh-Chang N., Daley G.Q. Lin28: primal regulator of growth and metabolism in stem cells. Cell Stem Cell 2013, 12:395-406.
54. Miyoshi N., Ishii H., Nagano H., Haraguchi N., Dewi D.L., Kano Y., et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell 2011, 8:633-638.
55. Matrai J., Chuah M.K., VandenDriessche T. Recent advances in lentiviral vector development and applications. Mol Ther 2010, 18:477-490.
56. Kumar P., Woon-Khiong C. Optimization of lentiviral vectors generation for biomedical and clinical research purposes: contemporary trends in technology development and applications. Curr Gene Ther 2011, 11:144-153.
57. Loh Y.H., Agarwal S., Park I.H., Urbach A., Huo H., Heffner G.C., et al. Generation of induced pluripotent stem cells from human blood. Blood 2009, 113:5476-5479.
58. Ye Z., Zhan H., Mali P., Dowey S., Williams D.M., Jang Y.Y., et al. Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood 2009, 114:5473-5480.
59. Kunisato A., Wakatsuki M., Kodama Y., Shinba H., Ishida I., Nagao K. Generation of induced pluripotent stem cells by efficient reprogramming of adult bone marrow cells. Stem Cells Dev 2010, 19:229-238.
60. Su R.J., Yang Y., Neises A., Payne K.J., Wang J., Viswanathan K., et al. Few single nucleotide variations in exomes of human cord blood induced pluripotent stem cells. PLoS One 2013, 8:e59908.
61. Polo J.M., Anderssen E., Walsh R.M., Schwarz B.A., Nefzger C.M., Lim S.M., et al. A molecular roadmap of reprogramming somatic cells into iPS cells. Cell 2012, 151:1617-1632.
62. + hematopoietic cells. Stem Cells 2001, 19:236-246.
63. Zhang X.B., Beard B.C., Trobridge G.D., Wood B.L., Sale G.E., Sud R., et al. High incidence of leukemia in large animals after stem cell gene therapy with a HOXB4-expressing retroviral vector. J Clin Invest 2008, 118:1502-1510.
64. Zhang X.B., Schwartz J.L., Humphries R.K., Kiem H.P. Effects of HOXB4 overexpression on ex vivo expansion and immortalization of hematopoietic cells from different species. Stem Cells 2007, 25:2074-2081.
65. Zhang X.B., Beard B.C., Beebe K., Storer B., Humphries R.K., Kiem H. Differential effects of HOXB4 on nonhuman primate short- and long-term repopulating cells. PLoS Med 2006, 3:e173.
66. Zufferey R., Donello J.E., Trono D., Hope T.J. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999, 73:2886-2892.
67. Ramezani A., Hawley T.S., Hawley R.G. Lentiviral vectors for enhanced gene expression in human hematopoietic cells. Mol Ther 2000, 2:458-469.
68. Warlich E., Kuehle J., Cantz T., Brugman M.H., Maetzig T., Galla M., et al. Lentiviral vector design and imaging approaches to visualize the early stages of cellular reprogramming. Mol Ther 2011, 19:782-789.
69. Hirai H., Tani T., Katoku-Kikyo N., Kellner S., Karian P., Firpo M., et al. Radical acceleration of nuclear reprogramming by chromatin remodeling with the transactivation domain of MyoD. Stem Cells 2011, 29:1349-1361.
70. Wang Y., Chen J., Hu J.L., Wei X.X., Qin D., Gao J., et al. Reprogramming of mouse and human somatic cells by high-performance engineered factors. EMBO Rep 2011, 12:373-378.
71. Papapetrou E.P., Tomishima M.J., Chambers S.M., Mica Y., Reed E., Menon J., et al. Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. Proc Natl Acad Sci U S A 2009, 106:12759-12764.
72. Martinez-Salas E., Pacheco A., Serrano P., Fernandez N. New insights into internal ribosome entry site elements relevant for viral gene expression. J Gen Virol 2008, 89:611-626.
73. Mizuguchi H., Xu Z., Ishii-Watabe A., Uchida E., Hayakawa T. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 2000, 1:376-382.
74. Hennecke M., Kwissa M., Metzger K., Oumard A., Kroger A., Schirmbeck R., et al. Composition and arrangement of genes define the strength of IRES-driven translation in bicistronic mRNAs. Nucleic Acids Res 2001, 29:3327-3334.
75. Yu X., Zhan X., D'Costa J., Tanavde V.M., Ye Z., Peng T., et al. Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells. Mol Ther 2003, 7:827-838.
76. Szymczak A.L., Workman C.J., Wang Y., Vignali K.M., Dilioglou S., Vanin E.F., et al. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 2004, 22:589-594.
77. Ibrahimi A., Vande Velde G., Reumers V., Toelen J., Thiry I., Vandeputte C., et al. Highly efficient multicistronic lentiviral vectors with peptide 2A sequences. Hum Gene Ther 2009, 20:845-860.
78. Carey B.W., Markoulaki S., Hanna J., Saha K., Gao Q., Mitalipova M., et al. Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc Natl Acad Sci U S A 2009, 106:157-162.
79. Kim J.H., Lee S.R., Li L.H., Park H.J., Park J.H., Lee K.Y., et al. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS One 2011, 6:e18556.
80. Chan H.Y., Sivakamasundari V., Xing X., Kraus P., Yap S.P., Ng P., et al. Comparison of IRES and F2A-based locus-specific multicistronic expression in stable mouse lines. PLoS One 2011, 6:e28885.
81. Kaji K., Norrby K., Paca A., Mileikovsky M., Mohseni P., Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009, 458:771-775.
82. Holst J., Vignali K.M., Burton A.R., Vignali D.A. Rapid analysis of T-cell selection in vivo using T cell-receptor retrogenic mice. Nat Methods 2006, 3:191-197.
83. Gao S.Y., Jack M.M., O'Neill C. Towards optimising the production of and expression from polycistronic vectors in embryonic stem cells. PLoS One 2012, 7:e48668.
84. Okita K., Nakagawa M., Hyenjong H., Ichisaka T., Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008, 322:949-953.
85. Sommer C.A., Sommer A.G., Longmire T.A., Christodoulou C., Thomas D.D., Gostissa M., et al. Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector. Stem Cells 2010, 28:64-74.
86. Seiler K., Soroush Noghabi M., Karjalainen K., Hummel M., Melchers F., Tsuneto M. Induced pluripotent stem cells expressing elevated levels of sox-2, oct-4, and klf-4 are severely reduced in their differentiation from mesodermal to hematopoietic progenitor cells. Stem Cells Dev 2011, 20:1131-1142.
87. Bitzer M., Armeanu S., Lauer U.M., Neubert W.J. Sendai virus vectors as an emerging negative-strand RNA viral vector system. J Gene Med 2003, 5:543-553.
88. Fusaki N., Ban H., Nishiyama A., Saeki K., Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci 2009, 85:348-362.
89. Seki T., Yuasa S., Oda M., Egashira T., Yae K., Kusumoto D., et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 2010, 7:11-14.
90. Nishimura K., Sano M., Ohtaka M., Furuta B., Umemura Y., Nakajima Y., et al. Development of defective and persistent Sendai virus vector: a unique gene delivery/expression system ideal for cell reprogramming. J Biol Chem 2011, 286:4760-4771.
91. Yu J., Hu K., Smuga-Otto K., Tian S., Stewart R., Slukvin I.I., et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009, 324:797-801.
92. Dorigo O., Gil J.S., Gallaher S.D., Tan B.T., Castro M.G., Lowenstein P.R., et al. Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells. J Virol 2004, 78:6556-6566.
93. Wang H., Cao H., Wohlfahrt M., Kiem H.P., Lieber A. Tightly regulated gene expression in human hematopoietic stem cells after transduction with helper-dependent Ad5/35 vectors. Exp Hematol 2008, 36:823-831.
94. Yoshioka N., Gros E., Li H.R., Kumar S., Deacon D.C., Maron C., et al. Efficient generation of human iPSCs by a synthetic self-replicative RNA. Cell Stem Cell 2013, 13:246-254.
95. Hou P., Li Y., Zhang X., Liu C., Guan J., Li H., et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 2013, 341:651-654.
96. Marion R.M., Blasco M.A. Telomere rejuvenation during nuclear reprogramming. Curr Opin Genet Dev 2010, 20:190-196.
97. Lapasset L., Milhavet O., Prieur A., Besnard E., Babled A., Aït-Hamou N., et al. Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. Genes Dev 2011, 25:2248-2253.
98. Kim K., Doi A., Wen B., Ng K., Zhao R., Cahan P., et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010, 467:285-290.
99. Lister R., Pelizzola M., Kida Y.S., Hawkins R.D., Nery J.R., Hon G., et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011, 471:68-73.
100. Nishino K., Toyoda M., Yamazaki-Inoue M., Fukawatase Y., Chikazawa E., Sakaguchi H., et al. DNA methylation dynamics in human induced pluripotent stem cells over time. PLoS Genet 2011, 7:e1002085.
101. Stadtfeld M., Apostolou E., Ferrari F., Choi J., Walsh R.M., Chen T., et al. Ascorbic acid prevents loss of Dlk1-Dio3 imprinting and facilitates generation of all-iPS cell mice from terminally differentiated B cells. Nat Genet 2012, 44:398-405. S1-2.
102. Boland M.J., Hazen J.L., Nazor K.L., Rodriguez A.R., Gifford W., Martin G., et al. Adult mice generated from induced pluripotent stem cells. Nature 2009, 461:91-94.
103. Zhao X.Y., Li W., Lv Z., Liu L., Tong M., Hai T., et al. IPS cells produce viable mice through tetraploid complementation. Nature 2009, 461:86-90.
104. Gore A., Li Z., Fung H.L., Young J.E., Agarwal S., Antosiewicz-Bourget J., et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011, 471:63-67.
105. Hussein S.M., Batada N.N., Vuoristo S., Ching R.W., Autio R., Närvä E., et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011, 471:58-62.
106. Ji J., Ng S.H., Sharma V., Neculai D., Hussein S., Sam M., et al. Elevated coding mutation rate during the reprogramming of human somatic cells into induced pluripotent stem cells. Stem Cells 2012, 30:435-440.
107. Young M.A., Larson D.E., Sun C.W., George D.R., Ding L., Miller C.A., et al. Background mutations in parental cells account for most of the genetic heterogeneity of induced pluripotent stem cells. Cell Stem Cell 2012, 10:570-582.
108. Zhao T., Zhang Z.N., Rong Z., Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011, 474:212-215.
109. Araki R., Uda M., Hoki Y., Sunayama M., Nakamura M., Ando S., et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 2013, 494:100-104.
110. Guha P., Morgan J.W., Mostoslavsky G., Rodrigues N.P., Boyd A.S. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 2013, 12:407-412.
111. Fong C.Y., Gauthaman K., Bongso A. Teratomas from pluripotent stem cells: A clinical hurdle. J Cell Biochem 2010, 111:769-781.
112. Kooreman N.G., Wu J.C. Tumorigenicity of pluripotent stem cells: biological insights from molecular imaging. J R Soc Interface 2010, 7:S753-S763.
113. Tang C., Lee A.S., Volkmer J.P., Sahoo D., Nag D., Mosley A.R., et al. An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat Biotechnol 2011, 29:829-834.
114. Lee M.O., Moon S.H., Jeong H.C., Yi J.Y., Lee T.H., Shim S.H., et al. Inhibition of pluripotent stem cell-derived teratoma formation by small molecules. Proc Natl Acad Sci U S A 2013, 110:14111-14112.
115. Cherry A.B., Daley G.Q. Reprogrammed cells for disease modeling and regenerative medicine. Annu Rev Med 2013, 64:277-290.
116. Kim K., Zhao R., Doi A., Ng K., Unternaehrer J., Cahan P., et al. Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat Biotechnol 2011, 29:1117-1119.
117. Kyba M., Perlingeiro R.C., Daley G.Q. HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell 2002, 109:29-37.
118. Hanna J., Wernig M., Markoulaki S., Sun C.W., Meissner A., Cassady J.P., et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007, 318:1920-1923.
119. Ran D., Shia W.J., Lo M.C., Fan J.B., Knorr D.A., Ferrell P.I., et al. RUNX1a enhances hematopoietic lineage commitment from human embryonic stem cells and inducible pluripotent stem cells. Blood 2013, 121:2882-2890.
120. Pereira C.F., Chang B., Qiu J., Niu X., Papatsenko D., Hendry C.E., et al. Induction of a hemogenic program in mouse fibroblasts. Cell Stem Cell 2013, 3:205-218.
121. + hematopoietic progenitor cells from nonhuman primate-induced pluripotent stem cells. Blood 2012, 120:e35-e44.
122. Han D.W., Tapia N., Hermann A., Hemmer K., Höing S., Araúzo-Bravo M.J., et al. Direct reprogramming of fibroblasts into neural stem cells by defined factors. Cell Stem Cell 2012, 10:465-472.
123. Song K., Nam Y.J., Luo X., Qi X., Tan W., Huang G.N., et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 2012, 485:599-604.
124. Ieda M., Fu J.D., Delgado-Olguin P., Vedantham V., Hayashi Y., Bruneau B.G., et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010, 142:375-386.
125. Huang P., He Z., Ji S., Sun H., Xiang D., Liu C., et al. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature 2011, 475:386-389.
126. Sekiya S., Suzuki A. Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Nature 2011, 475:390-393.
127. Kim J., Efe J.A., Zhu S., Talantova M., Yuan X., Wang S., et al. Direct reprogramming of mouse fibroblasts to neural progenitors. Proc Natl Acad Sci U S A 2011, 108:7838-7843.
128. Efe J.A., Hilcove S., Kim J., Zhou H., Ouyang K., Wang G., et al. Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nat Cell Biol 2011, 13:215-222.
129. Wang L., Wang L., Huang W., Su H., Xue Y., Su Z., et al. Generation of integration-free neural progenitor cells from cells in human urine. Nat Methods 2013, 10:84-89.
130. Lu J., Liu H., Huang C.T., Chen H., Du Z., Liu Y., et al. Generation of integration-free and region-specific neural progenitors from primate fibroblasts. Cell Rep 2013, 3:1580-1591.
131. Morris S.A., Daley G.Q. A blueprint for engineering cell fate: current technologies to reprogram cell identity. Cell Res 2013, 23:33-48.
132. Zhou Q., Brown J., Kanarek A., Rajagopal J., Melton D.A. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 2008, 455:627-632.
133. Jayawardena T.M., Egemnazarov B., Finch E.A., Zhang L., Payne J.A., Pandya K., et al. MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circ Res 2012, 110:1465-1473.
134. Qian L., Huang Y., Spencer C.I., Foley A., Vedantham V., Liu L., et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 2012, 485:593-598.
135. Gaj T., Gersbach C.A. Barbas CF 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 2013, 31:397-405.
136. Levitskaya J., Coram M., Levitsky V., Imreh S., Steigerwald-Mullen P.M., Klein G., et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995, 375:685-688.